Multiple Sclerosis Trial, Recruiting NCT03600779 Sponsor: Assistance Publique Hopitaux De Marseille Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT03600779
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult aged between 18 and 45 years old (male or female)
  • You are covered by health insurance
  • You have read, understood, and freely signed a consent form agreeing to take part
  • (For patients only) You have been diagnosed with relapsing-remitting multiple sclerosis (a form of MS with flare-ups and periods of recovery) based on specific diagnostic guidelines (McDonald 2010 criteria)
  • (For patients only) You have had MS for less than 5 years
  • (For patients only) You may or may not currently be taking a first-line MS medication
  • (For patients only) At least one active area of inflammation was found on your initial brain MRI scan using a contrast dye called Gadolinium

Who may not be able to join:

  • (For patients only) You have a progressive form of MS (such as primary progressive or secondary progressive MS), rather than the relapsing-remitting form
  • You have a medical reason that prevents you from having an MRI scan, such as a pacemaker, metal fragments in your body, or severe claustrophobia (fear of enclosed spaces)
  • You have difficulties that might make it hard to complete the exam, such as trouble understanding instructions, confusion, uncontrolled movements, or difficulty lying still for a long period of time
  • You are unable to give informed consent due to difficulties with understanding, reduced alertness, or confusion
  • You are currently pregnant or breastfeeding
  • You have a history of a neurological (brain or nerve) or psychiatric (mental health) condition
  • You are under legal guardianship or a similar supervised care arrangement

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: EMILIE GARRIDO PRADALIE, APHM

Phone: +33 491388204

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 June 2018
Est. completion
13 February 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

ihMTR ratio at 1.5TMRI; Magnetic transfert (MT) at 1.5TMRI; Myelin water fraction at 1.5TMRI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov